Press Room
  Date Title View
Feb 15, 2000
San Mateo, CA, February 15, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced plans to move forward with the next stage of its phase 2 development program for CPX, a novel PRT (protein repair therapy) for cystic fibrosis (CF). SciClone, working closely with scientists and clinical investig...
PDF
Feb 3, 2000
San Mateo, CA, February 3, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 1999.For the year, the Company reported total revenue of $9,397,000, a 152% increase over the $3,725,000 reported for 1998. Sales of ZADAXINÃ’, the Company's host immune system enhancer (...
PDF
Jan 27, 2000
San Mateo, CA, January 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the start of a U.S. Phase 2 hepatitis B study using ZADAXIN, the Company's host immune system enhancer (h-ISE), in combination with lamivudine, an FDA-approved nucleoside analogue. The study, conducted at Loyola U...
PDF
Jan 19, 2000
San Mateo, CA, January 19, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the completion of a $6,100,000 private placement with its largest institutional shareholder, The Brown Simpson Strategic Growth Funds. The newly acquired funds will be directed toward the distribution of ZADAXIN...
PDF
Nov 19, 1999
San Mateo, CA, November 19, 1999 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced the appointment of Craig R. Olson as Regional Managing Director, Latin America and Kenneth R. Cowan as Regional Managing Director, Middle East for the Company's international subsidiary, SciClone Pharmaceuticals International, Ltd. Olson and Cowan become SciClone...
PDF
FirstPrevious
...
41